Core Viewpoint - The article discusses a securities class action against BlackRock TCP Capital Corp, highlighting allegations of misleading statements and failure to disclose critical financial information, with a deadline for investors to seek lead plaintiff status by April 6, 2026 [1][2]. Financial Performance - BlackRock TCP's portfolio significantly weakened during the 2024 fiscal year, with the number of portfolio companies on non-accrual status more than doubling, leading to a 289% increase in debt investments on non-accrual status at cost, rising from 3.7% to 14.4% of the portfolio [1][2]. - The company's net asset value (NAV) fell by 22.44% year over year to $9.23 per share, while total losses, both realized and unrealized, surged to $194.9 million for the fiscal year, marking a 186% increase year over year, largely due to a $72.3 million net unrealized loss in the fourth quarter [1][2]. - Following the financial disclosures, BlackRock TCP's stock price dropped by $0.90, or 9.64%, to close at $8.44 per share on February 27, 2025, and further fell by $0.76, or 12.97%, to close at $5.10 per share on January 26, 2026, after revealing a NAV per share of $7.05 to $7.09, which was 19% lower than the previous quarter and 23.4% lower than the prior year [1][2]. Legal Proceedings - The complaint alleges that BlackRock TCP and its executives violated federal securities laws by making false or misleading statements and failing to disclose that the company's investments were not being appropriately valued, and that their portfolio restructuring efforts were ineffective [1][2]. - Investors who purchased securities between November 6, 2024, and January 23, 2026, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal rights and options regarding the class action [1][2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Beyond Meat, Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by March 24, 2026 [1][2] Group 1: Allegations Against Beyond Meat - The complaint alleges that Beyond Meat and its executives made false and misleading statements regarding the book value of certain long-lived assets, which exceeded their fair value, indicating a likely need for a material non-cash impairment charge [1][2] - It is claimed that these issues could impair Beyond Meat's ability to timely file periodic reports with the U.S. Securities and Exchange Commission (SEC) [1][2] - As a result of these allegations, the public statements made by the defendants were materially false and misleading at all relevant times [1][2] Group 2: Stock Price Impact - On November 3, 2025, Beyond Meat announced a delay in reporting its Q3 2025 financial results, leading to a stock price drop of $0.265 per share, or 16.01%, closing at $1.39 per share [1][2] - Following the announcement of Q3 2025 financial results on November 10, 2025, which included a loss from operations of $112.3 million and $77.4 million in non-cash impairment charges, the stock price fell by $0.12 per share, or 8.96%, closing at $1.22 per share [1][2] - On November 11, 2025, during a conference call, the CFO disclosed that the total impairment amount of $77.4 million was allocated to property, plant, and equipment (PP&E), operating lease ROU assets, and prepaid lease costs, resulting in an additional stock price decline of $0.105 per share, or 8.61%, closing at $1.115 per share on November 12, 2025 [1][2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. (AGL) for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by March 2, 2026 [1] Summary by Relevant Sections Legal Action - A federal securities class action has been filed against agilon health, alleging that the company and its executives made false and misleading statements regarding their financial guidance and business operations [1] - The complaint claims that the defendants issued guidance for 2025 that they knew or should have known was unattainable due to industry headwinds [1] - The lawsuit also alleges that the defendants overstated the financial impact of strategic actions taken to reduce risk, leading to materially false statements about the company's prospects [1] Financial Impact - On August 4, 2025, agilon health reported its second-quarter results, indicating that industry challenges were more severe than previously anticipated, and subsequently suspended its full-year 2025 financial guidance [1] - Following this announcement, agilon health's stock price dropped by 51.5% on August 5, 2025, reflecting the market's reaction to the revised outlook [1] Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members, overseeing the litigation on behalf of the group [1] - Any member of the class can apply to serve as lead plaintiff or choose to remain an absent class member, with their ability to recover not affected by this decision [1]

Core Viewpoint - Vistagen Therapeutics is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1]. Group 1: Legal Action and Allegations - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics and reminds investors of the March 16, 2026 deadline to seek the role of lead plaintiff in the class action [1]. - The complaint alleges that Vistagen and its executives violated federal securities laws by making false assertions about the likelihood of success for fasedienol based on prior clinical trial results [1]. - The lawsuit claims that these misleading statements caused investors to purchase Vistagen's stock at artificially inflated prices [1]. Group 2: Clinical Trial Results - On December 17, 2025, Vistagen announced that its PALISADE-3 clinical trial for fasedienol failed to meet its primary efficacy endpoint, showing no statistically significant improvement in anxiety reduction compared to placebo [1]. - Following the announcement of the failed trial results, Vistagen's stock price plummeted over 81%, opening at $0.88 per share [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BellRing Brands, Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by March 23, 2026 [1] Group 1: Legal Action and Allegations - The complaint alleges that BellRing and its executives made false or misleading statements regarding the strength and sustainability of the company's sales growth, as well as the competitive landscape affecting product demand [1] - On May 5, 2025, BellRing disclosed that several key retailers had reduced their weeks of supply, which would negatively impact Q3 2025 growth, leading to a stock price drop of $14.88 per share, or 19%, from $78.43 to $63.55 [1] - Following disappointing quarterly consumption results for Premier Protein RTD Shakes on August 4, 2025, the stock fell by $17.46 per share, or nearly 33%, from $53.64 to $36.18 [1] Group 2: Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members, overseeing the litigation on behalf of the class [1] - Any member of the putative class can move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi encourages individuals with information regarding BellRing's conduct to come forward, including whistleblowers and former employees [1]

Core Viewpoint - Ultragenyx Pharmaceutical Inc is facing a federal securities class action due to allegations of making false or misleading statements regarding the efficacy of its drug setrusumab for Osteogenesis Imperfecta, leading to significant stock price declines following study failures [1][2] Summary by Relevant Sections Company Overview - Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is under investigation by Faruqi & Faruqi, LLP for potential securities law violations related to its clinical trials [1] Allegations - The complaint alleges that Ultragenyx and its executives misrepresented the reliability of information regarding setrusumab's effects and downplayed risks associated with the Phase III Orbit study [1] - It is claimed that Ultragenyx failed to disclose that the Phase II results lacked a placebo control group, which could have influenced the perceived efficacy of the treatment [1] Stock Performance - Following the announcement on July 9, 2025, that the Phase III Orbit study did not achieve statistical significance, Ultragenyx's stock price fell by over 25% [1] - On December 29, 2025, after revealing that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, the stock price dropped by more than 42% [2] Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is April 6, 2026 [1] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [2]

Core Insights - Coupang, Inc. experienced a significant drop in share price, falling over 13% due to a report of an additional 165,000 user data being leaked, compounding the previously reported 33 million users affected by a major security breach [1][2] - The interim CEO, Harold Rogers, is under investigation for potential perjury related to statements made about the breach, specifically regarding the involvement of the Korean government in the investigation [2] - A securities class action lawsuit has been initiated, representing investors who acquired Coupang securities between May 7, 2025, and December 16, 2025, due to alleged misleading statements about the company's cybersecurity measures [3][4] Company Developments - The data breach reportedly affected 33.7 million accounts and was executed by a former employee using authentication keys that remained valid post-departure, leading to a $1.2 billion compensation plan and the resignation of the CEO, resulting in a loss of over $8 billion in market value [4] - Following the class period, Coupang filed a report with the SEC indicating that its investigation was conducted under the direction of the government, which raises questions about the accuracy of previous statements made by the company [5] - The investigation is focused on why Coupang's security measures failed to detect unauthorized access to sensitive customer data by a former employee [6]

Core Viewpoint - Hagens Berman is notifying investors in Fermi Inc. (NASDAQ: FRMI) about a pending securities class action related to alleged misrepresentations regarding the demand for its Project Matador AI data center and the stability of its primary tenant [1] Summary by Relevant Sections Allegations of Misrepresentation - The lawsuit claims that Fermi misrepresented the demand for its flagship Project Matador and the reliability of its primary anchor tenant [1] - The complaint states that the misstatements were revealed on December 12, 2025, when Fermi announced the termination of a $150 million Advance in Aid of Construction Agreement (AICA) by its first tenant, leading to a nearly 34% drop in stock price [1] Class Action Details - The class action seeks to represent purchasers of Fermi Inc. common stock related to the October 2025 IPO and securities acquired between October 1, 2025, and December 11, 2025 [1] - Following the announcement of the AICA termination, Fermi's stock price fell 33.8% in one day, trading as low as $8.59 per share, a 59% decline from the IPO price of $21.00 per share [1] Concealed Risks and Overstatements - The complaint alleges that Fermi concealed risks associated with relying on a single tenant's funding commitment for Project Matador and overstated the actual demand for its multi-gigawatt capacity to attract investors [1]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Richtech To Contact Him Directly To Discuss Their OptionsIf you purchased or acquiring securities in Richtech between January 27, 2026 and 12:00 PM ET on January 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Cor ...

Core Viewpoint - Coupang, Inc. is facing significant challenges following a major data breach that has led to a substantial drop in share price and legal actions against the company [1][4]. Group 1: Data Breach and Financial Impact - On February 5, 2026, Coupang's shares fell over 13% after a report revealed an additional 165,000 users' data was leaked, compounding the previously reported 33 million users affected [1]. - The breach, which impacted 33.7 million accounts, was allegedly executed by a former employee using authentication keys that remained valid long after their departure, resulting in a $1.2 billion compensation plan and a CEO resignation, wiping out over $8 billion in market value [4]. Group 2: Legal and Regulatory Developments - An interim CEO, Harold Rogers, is under investigation by South Korean authorities for potential perjury related to statements made about the breach during a National Assembly hearing [2]. - A securities class action lawsuit has been initiated, seeking to represent investors who acquired Coupang securities between May 7, 2025, and December 16, 2025, alleging that the company misled investors about its cybersecurity measures [3][4]. Group 3: Company Statements and Investigations - Following the breach, Coupang filed a report with the SEC stating that its investigation was conducted under the direction of the government, which has raised questions about the accuracy of previous statements made by the company [5]. - The firm Hagens Berman is leading an investigation into the claims, focusing on why Coupang's threat visibility failed to detect the former employee's access to sensitive customer data [6].